Sign in
CompletedPhase 1

Mirtazapine for Chronic Insomnia in Older Adults

Key facts

Who runs it
Centre hospitalier de l'Université de Montréal (CHUM)
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
60 people enrolled
Started
1 Oct 2022
Ended
30 Jul 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Mirtazapine 7.5 MG Oral Tablet once daily at bedtime
  • Placebo oral tablet once daily at bedtime
Record updated
12 August 2024

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 65 years and older
  • A report of sleep initiation or maintenance problems
  • An adequate opportunity and circumstances to sleep,
  • To have at least one daytime consequence in relation to sleep complaint
  • Sleep disorder and daytime consequences occur at least 3 times a week
  • Duration of sleep disorder and daytime consequences for at least 3 months
  • Sleep complaint cannot be explained by a sleep disorder other than chronic insomnia

Who cannot take part

  • Use of drug for insomnia
  • Cognitive Behavioural Therapy for insomnia
  • Active psychiatric illness
  • Parkinson's disease
  • Major Neurocognitive disorders
  • Contrindication to mirtazapine
  • Use of Melatonin
  • More than one fall in the last 3 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Insomnia is highly prevalent in the older adult population. The pharmacolgical management of chronic insomnia includes benzodiazepines and Z-drugs (zolpidem, zopiclone). Although these drugs are indicated for insomnia, they are not without side effects. These drugs are associated with cognitive impairment, rebound insomnia, falls and addiction. Mirtazapine has a hypnotic and sedative effect related to the blocking of histamine-1 receptors. No clinical trials has evaluated the efficacy and safety of mirtazapine for insomnia in the older population.

Read full original descriptionShow less

The goal of the study is to assess the efficacy and safety of mirtazapine compared to a placebo in older adults with chronic insomnia.

This prospective double-blind placebo controlled trial will be conducted in adults 65 years and older with chronic insomnia. The treatment group will receive mirtazapine 7.5 mg at bedtime for 28 days and the control group will receive a matching placebo for 28 days. The sample size for the pilot study will be 60 subjects, 30 subjects in the treatment group and 30 subjects in the control group. The efficacy of mirtazapine will be measured using the Insomnia Severity Index and the Pittsburgh Sleep Quality Index. Safety will be monitored during the study

The 2 groups in the trial

  • TreatmentTreatment being tested

    Mirtazapine 7.5 mg

    Treatment: Mirtazapine 7.5 MG Oral Tablet once daily at bedtime

  • ControlPlacebo, for comparison

    Matching placebo

    Treatment: Placebo oral tablet once daily at bedtime

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of Mirtazapine in the Treatment of Chronic Insomnia in Older Adults : The MIRAGE Study
Publications
Record updated
12 August 2024